Phase II trial evaluating axitinib for patients with unresectable, recurrent, or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).Assuntina G. Sacco, Francis P. Worden, Thomas E. Carey et al.|Journal of Clinical Oncology|2014Cited by 2